Orthopediatrics’ COO and CFO Hite Fred sells $160,172 in stock

Published 18/03/2025, 19:54
Orthopediatrics’ COO and CFO Hite Fred sells $160,172 in stock

In a recent filing with the Securities and Exchange Commission, Orthopediatrics Corp (NASDAQ:KIDS), a company currently valued at $614 million with a "GOOD" InvestingPro Financial Health score, disclosed that Fred Hite, the company’s Chief Operating Officer and Chief Financial Officer, sold 6,443 shares of common stock on March 18, 2025. The shares were sold at a price of $24.86 each, totaling approximately $160,172.

This transaction follows an acquisition of 63,342 shares on March 15, 2025, which were obtained without any monetary exchange. After these transactions, Hite holds a total of 207,989 shares, including restricted stock awards totaling 150,360 shares. The recent sale was conducted to satisfy tax withholding obligations upon the vesting of restricted shares. The company maintains strong liquidity with a current ratio of 6.98 and operates with moderate debt levels, though analysts anticipate continued unprofitability in the current fiscal year.

In other recent news, OrthoPediatrics Corporation reported its fourth-quarter 2024 earnings, revealing a larger-than-expected loss with an EPS of -$0.69, missing the forecasted -$0.30. However, the company’s revenue of $52.7 million exceeded expectations of $50.72 million, marking a 40% year-over-year increase. The U.S. revenue saw a significant 52% rise, contributing to the overall revenue growth. For 2025, OrthoPediatrics projects revenue between $235 million and $242 million, representing a 15-18% growth. Stifel analysts have adjusted the price target for OrthoPediatrics to $32.00 from $40.00, maintaining a Buy rating, reflecting a positive outlook despite the earnings miss. Management has highlighted several key sales drivers for 2025, including expanding the Specialty Bracing franchise and a strong U.S. Trauma business. These developments suggest potential market share gains and a broadening product portfolio. Additionally, OrthoPediatrics anticipates achieving its first positive free cash flow by Q4 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.